VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ERIC 2022 | The impact of IGHV mutational status in treatment decisions in CLL

Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, comments on the prognostic value of IGHV mutational status in chronic lymphocytic leukemia (CLL), discussing the impact of these mutations on response to chemoimmunotherapy and targeted therapy. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter